Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 133981
2. Dolezel M, Odrazka K, Vanasek J, Vaculikova M, Vlkova-Sefrova J, Jansa J, Macingova Z, Brodak M, Hartmann I, Melichar B: Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy. J BUON; 2013 Oct-Dec;18(4):949-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.
  • PURPOSE: To retrospectively investigate the impact of prostate specific antigen (PSA) level after neoadjuvant androgen- deprivation therapy (ADT) on biochemical relapse-free survival in patients with prostate cancer who received radical radiotherapy (RT).
  • METHODS: Between March 2003 and March 2008, 128 men with localized prostate cancer underwent neoadjuvant ADT for 4-6 months followed by radical RT.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Kallikreins / blood. Neoadjuvant Therapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Grading. Patient Selection. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24344022.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein-related peptidase 3, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


3. Inamoto T, Komura K, Watsuji T, Azuma H: Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer. Clin Med Insights Oncol; 2011;5:101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.
  • OBJECTIVES: To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical factors.
  • METHODS: A total of 176 patients with localized prostate cancer underwent HIFU therapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):698-702 [12377320.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53 [12738319.001]
  • [Cites] Urology. 2005 Aug;66(2):327-31 [16040084.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1355-9 [16406391.001]
  • [Cites] Radiother Oncol. 2008 Jul;88(1):102-7 [18453022.001]
  • [Cites] J Androl. 2008 Sep-Oct;29(5):534-9 [18567642.001]
  • [Cites] Urology. 2009 Dec;74(6):1183-90 [19428077.001]
  • [Cites] Eur Urol. 2010 Oct;58(4):559-66 [20619958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):426-33 [17869662.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1431-7 [17544597.001]
  • (PMID = 21603245.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3095026
  • [Keywords] NOTNLM ; HIFU / PSA / prostate cancer
  •  go-up   go-down


5. Gelblum DY, Potters L: Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer.
  • PURPOSE: As transperineal interstitial permanent prostate brachytherapy (TIPPB) grows in acceptance as an option in the treatment of organ-confined prostate cancer, its associated toxicities are being defined.
  • This clinical report documents rectal toxicity from a large cohort of men treated by a single practitioner for adenocarcinoma of the prostate.
  • CONCLUSION: TIPPB is a tolerable and acceptable treatment option when used alone in early-stage, organ-confined adenocarcinoma of the prostate and in conjunction with EBRT in more advanced disease.
  • [MeSH-major] Brachytherapy / adverse effects. Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Rectal Diseases / etiology


6. Mikolajczyk SD, Rittenhouse HG: Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med; 2003 Jun;52(2):86-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
  • The inactive precursor of PSA, proPSA, is associated with prostate tumors.
  • ProPSA is comprised of native proPSA as well as truncated proPSA forms, [-2]pPSA and [-4]pPSA, which have been shown to be more cancer-associated than native proPSA.
  • Free PSA in prostate cancer serum contains a median of 28% BPSA and 32% proPSA, though each form of PSA can range from 0 to more than 50% in individual samples.
  • Early studies revealed that proPSA significantly increases the specificity for prostate cancer, especially in the 2-4 ng/ml PSA range.
  • It is estimated that 20-30% of men with PSA values from 2-4 ng/ml have prostate cancer.
  • ProPSA represents a more cancer-specific form of PSA that better discriminates prostate cancer from BPH.
  • [MeSH-major] Prostate-Specific Antigen / analysis. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis. Protein Precursors / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Sensitivity and Specificity


7. Uchida T: Editorial Comment to Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. Int J Urol; 2010 Nov;17(11):930
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial Comment to Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer.
  • [MeSH-major] Neoadjuvant Therapy / methods. Prostatic Neoplasms / therapy. Transurethral Resection of Prostate / methods. Ultrasound, High-Intensity Focused, Transrectal / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Urol. 2010 Nov;17(11):924-30 [20969640.001]
  • (PMID = 20969641.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Australia
  •  go-up   go-down


8. Dayes IS, Parpia S, Gilbert J, Julian JA, Davis IR, Levine MN, Sathya J: Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Int J Radiat Oncol Biol Phys; 2017 Sep 01;99(1):90-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate.
  • PURPOSE: To determine the impact on long-term survival from the addition of brachytherapy to external beam radiation therapy (EBRT) in patients with prostate cancer.
  • METHODS AND MATERIALS: Between 1992 and 1997, 104 men with cT2-3, surgically staged node-negative prostate cancer were randomized to receive either EBRT (40 Gy/20 fractions) with iridium implant (35 Gy/48 hours) or EBRT alone (66 Gy/33 fractions) to the prostate.
  • According to T stage, Gleason score, and prostate-specific antigen level, 60% of patients had high-risk disease.
  • There have been 75 deaths, including 21 from prostate cancer and 25 from second cancers.
  • No patients developing a second cancer have died from prostate cancer.
  • Similarly, there was no difference in prostate cancer-specific deaths: 9 (18%) patients in the implant arm compared with 12 (23%) in the EBRT arm (HR 0.79, 95% CI 0.34-1.87).
  • There was no statistically significant difference in the number of patients developing metastatic disease: 10 (20%) in the implant arm and 15 (28%) in the EBRT arm (HR 0.70, 95% CI 0.32-1.57).
  • CONCLUSIONS: Despite a dramatic reduction of biochemical recurrence rates, the addition of iridium implant to EBRT did not translate into improved overall survival or prostate cancer-specific survival.
  • [MeSH-major] Brachytherapy / methods. Iridium Radioisotopes / therapeutic use. Prostatic Neoplasms / mortality. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Cause of Death. Follow-Up Studies. Humans. Male. Neoplasms, Second Primary / mortality. Prostate-Specific Antigen / blood. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28816169.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


9. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC: Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. J Urol; 2017 Feb;197(2S):S200-S207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
  • : To compare the efficacy of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer, we conducted a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandom-E or Tandem-R assays) and digital rectal examination.
  • /l. or digital rectal examination was suspicious, even if transrectal ultrasonography revealed no areas suspicious for cancer.
  • Of 1,167 biopsies performed cancer was detected in 264.
  • PSA detected significantly more tumors (82%, 216 of 264 cancers) than digital rectal examination (55%, 146 of 264, p = 0.001).
  • The cancer detection rate was 3.2% for digital rectal examination, 4.6% for PSA and 5.8% for the 2 methods combined.
  • Of 160 patients who underwent radical prostatectomy and pathological staging 114 (71%) had organ confined cancer: PSA detected 85 (75%) and digital rectal examination detected 64 (56%, p = 0.003).
  • Use of the 2 methods in combination increased detection of organ confined disease by 78% (50 of 64 cases) over digital rectal examination alone.
  • We conclude that the use of PSA in conjunction with digital rectal examination enhances early prostate cancer detection.
  • Prostatic biopsy should be considered if either the PSA level is greater than 4 μg.
  • /l. or digital rectal examination is suspicious for cancer, even in the absence of abnormal transrectal ultrasonography findings.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 1994 American Urological Association, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28012755.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; antigens / diagnosis / neoplasm / prostatic neoplasms / ultrasonography
  •  go-up   go-down


10. Pellizzon AC: Interstitial high-dose-rate brachytherapy and local anesthesia for prostate cancer: a feasibility report. Curr Urol Rep; 2008 Jan;9(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial high-dose-rate brachytherapy and local anesthesia for prostate cancer: a feasibility report.
  • High-dose-rate brachytherapy (HDR-BT) to treat prostate cancer is usually performed with the patient under general or spinal anesthesia.
  • Eleven patients with locally advanced prostate cancer, classified as intermediate or high risk, were treated based on an institutional protocol combining HDR-BT and hypofractionated external-beam radiotherapy.
  • We conclude that HDR-BT for prostate cancer with the patient under local anesthesia is efficient in terms of resource use and personnel time and will facilitate and expand the use of HDR-BT at our institution and others with few beds.
  • [MeSH-major] Anesthesia, Local. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2003 Apr;13(2):98-108 [12728439.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22 [11814067.001]
  • [Cites] J Am Med Assoc. 1960 Apr 2;172:1493-8 [13823696.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):401-6 [10487563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Urol. 2004 Mar;171(3):1105-8 [14767280.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):681-3 [8948353.001]
  • [Cites] Radiother Oncol. 2003 Feb;66(2):167-72 [12648788.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23 [16879929.001]
  • [Cites] J Urol. 1986 Apr;135(4):719-21 [3959191.001]
  • (PMID = 18366973.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement